Back to discover
Drug

Bromfenac sodium sesquihydrate

Approved · EMA

Also known as bromfenac (as sodium sesquihydrate).

RxNorm1941015
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Yellox (EMA)

Regulatory2011-05-18EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Bromfenac sodium sesquihydrate
Aliases & brands
bromfenac (as sodium sesquihydrate)
RxNorm CUI
1941015
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2011-05-18
Latest approval
2011-05-18
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2011-05-18Approval
Approval: Yellox (EMA)

Indication: Treatment of postoperative ocular inflammation following cataract extraction in adults.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Regulatory event sources are credited in the Regulatory Timeline above.